Long/short equity, research analyst, biotech, healthcare

Sunesis Pharmaceuticals, Inc. Offers A Moderate Risk 80% Return On The Short Side

When biotech companies implode, they often do so in spectacular fashion. In the last year alone, we've seen Ariad Pharmaceuticals, Geron Corp., and Sarepta Therapeutics - just to name a few, post eye-popping single day losses following negative events surrounding critical products within their respective portfolios.

Sunesis Pharmaceuticals (NASDAQ:SNSS) looks like it will be the next name to go belly-up in this risky industry, despite a bevy of positive statements and business moves by management suggesting otherwise.

Getting right to the point, I believe there are three compelling indicators that the company's pivotal Phase 3 trial for Qinprezo (vosaroxin), known as VALOR, as a treatment for refractory or relapsed AML will fail to meets its primary...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details